Lenz joined the WSGW team in 1978. He was the on-air personality for the “Four for the Morning” and “Terry and Dave in the ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

One Billings city official says plans for a new state mental hospital could be finalized by the end of this month, but state ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Lenz Therapeutics (NASDAQ:LENZ) reported GAAP revenue of $5.0 million for Q2 2025, far surpassing the $0.71 million GAAP analyst estimate, due to licensing deals rather than product sales. Net ...

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

Tony Schick, Oregon Public Broadcasting This article was produced for ProPublica’s Local Reporting Network in partnership with Oregon Public Broadcasting. Sign up for Dispatches to get our stories in ...